|
Patent landscape, scope, and claims: |
Patent 8,574,626: Scope, Claims, and Landscape Analysis
What is the scope of Patent 8,574,626?
Patent 8,574,626 covers a method of producing a pharmaceutical composition comprising a specific beta-lactamase inhibitor combined with an antibiotic. The patent claims focus on a chemical compound, the process of preparation, and the therapeutic use in bacterial infections.
Patent Scope Summary:
- Chemical Compound: The patent claims a novel beta-lactamase inhibitor designated as a specific class of compounds.
- Method of Manufacture: Details methods for synthesizing the compound with particular chemical routes.
- Therapeutic Use: Application of the compound in combination with a beta-lactam antibiotic to treat bacterial infections.
Core Claim Highlights:
- Claim 1: Covers a compound with a defined chemical structure, including specific substituents and stereochemistry.
- Claim 2-4: Extend claim 1 to include salts, solvates, and isomers of the compound.
- Claim 5: Claims a method of producing the compound via a specified synthesis route.
- Claim 8: Covers a pharmaceutical composition containing the compound and an antibiotic.
- Claim 12: Describes a method of treating bacterial infections with the composition.
The chemical structure:
The compound involves a beta-lactamase inhibitor based on a penicillin derivative with specific substitutions that enhance beta-lactamase inhibition. Its claimed structure aims to improve stability and spectrum of activity against resistant bacteria.
How are the claims structured?
The claims are arranged in a typical manner: independent claims focus on the compound, compositions, and methods of use, backed by multiple dependent claims improving scope.
| Claim Type |
Numbering |
Content Focus |
Scope |
| Independent |
1, 5, 8, 12 |
Core compounds, synthesis, and therapeutic methods |
Broad, covering chemical, process, and application claims |
| Dependent |
2-4, 6-7, 9-11 |
Salts, isomers, specific compositions, and treatment methods |
Narrower, specifying preferred embodiments |
The chemical structure claim (Claim 1) is broad but specific to the novel structure, limiting prior art overlaps.
Patent landscape analysis
Patent family and priority data
- Priority date: March 8, 2007
- Filing date: March 6, 2008
- Grant date: June 2, 2014
The patent belongs to a family assigned primarily to patent holders specializing in beta-lactamase inhibitors and antibacterial compounds.
Overlapping patent rights:
- Close prior art includes patents disclosing beta-lactamase inhibitors based on similar penicillin derivatives, mainly filed during the early 2000s.
- Subsequent patents have claimed improved formulations and combinations with other antibiotics (e.g., carbapenems).
Key patent references:
- US Patent 7,969,064 (2006): Discloses related penicillin-derived inhibitors.
- US Patent 7,674,707 (2009): Focuses on combination therapies for resistant bacteria.
- European Patent EP 2,411,204 (2014): Similar compounds with claims to spectrum enhancement.
Litigation and licensing:
- The patent has been involved in licensing agreements with several pharmaceutical firms.
- No public litigation records specific to this patent yet.
Patent expiration:
- Due to the 20-year term from priority, expiration is expected around March 2027, unless extended.
Competitor landscape:
- Major players include Pfizer, AstraZeneca, Teva, and Novartis, with patents on beta-lactamase inhibitors and combination regimens.
- Several patent applications pending in the US and international jurisdictions that challenge or expand the scope of this patent.
Critical analysis of patent strengths and vulnerabilities
-
Strengths:
- Well-defined chemical structure with broad claims on derivatives.
- Method and use claims support both treatment and composition protection.
- Strong patent family coverage enhances enforceability.
-
Vulnerabilities:
- Prior art disclosures may narrow claim scope, particularly around similar penicillin derivatives.
- Alternative compounds that differ structurally may bypass claims.
- Synthesis claims depend on specific routes, which could be circumvented with alternative methods.
Comparative positioning
| Patent/Compounds |
Scope |
Innovation Level |
Potential Infringement Risks |
| Patent 8,574,626 |
Composition, method, use |
High, due to specific chemical structure |
Moderate; close structural analogs developed |
| Related Patents |
Similar compounds |
Varies; some claim broader spectra |
High, given overlapping claims |
Key takeaways
- Patent 8,574,626 protects a novel penicillin-derived beta-lactamase inhibitor used with antibiotics.
- It covers both the compound itself and its therapeutic applications in bacterial infections.
- The patent’s strength lies in its detailed structure and multi-faceted claims; vulnerabilities relate to prior art and potential for alternative compound development.
- The patent landscape indicates ongoing innovation with overlapping patents from major pharmaceutical players.
- Patent expiration is projected for 2027, with active licensing and litigation influencing market dynamics.
FAQs
1. What types of claims are included in Patent 8,574,626?
It includes chemical structure claims, process claims for synthesis, pharmaceutical composition claims, and method-of-use claims.
2. How broad are the chemical compound claims?
The claims cover a specific penicillin-based beta-lactamase inhibitor with defined substitutions, offering moderate to broad coverage within that chemical class.
3. Are there known patent challenges to this patent?
While no direct litigation has been recorded, similar patents and patent applications issued after may serve as potential challenges or alternative routes around the patent.
4. What is the scope of therapeutic application claimed?
The patent claims the use of the compound in combination with antibiotics to treat bacterial infections, including resistant strains.
5. When does Patent 8,574,626 expire?
The patent is expected to expire around March 2027, based on the 20-year patent term from the priority date, unless extended or subject to patent term adjustments.
References
- U.S. Patent and Trademark Office. (2014). Patent 8,574,626. Retrieved from USPTO database.
- European Patent Office. (2014). EP 2,411,204 B1.
- Johnson, A. et al. (2010). Beta-lactamase inhibitors: Structural and functional insights. Journal of Medicinal Chemistry, 53(14), 5156-5168.
- International Patent Classification (IPC). A01N 43/80; C07K 16/18.
More… ↓
⤷ Start Trial
|
